3rd mRNA-Based Therapeutics Summit Europe | Berlin, Germany | 23rd-25th January 2024

The eagerly anticipated mRNA-Based Therapeutics Summit Europe returns to Berlin this January for the third year as Europe's largest and most important gathering of mRNA experts.

Showcasing exclusive new data from the trailblazers and thought leaders in the field, join 250+ industry specialists including the likes of the MHRA, EMA, BioNTech, CureVac, Ziphius Vaccines, Moderna and more across 3 days to uncover groundbreaking discovery, pre-clinical and clinical insights in mRNA therapeutic and vaccine development to fast-track R and D and pipeline expansions.

Prices:
Conference + Focus Day OR Workshop Day - Drug Developer Pricing: EUR 4446.00,
Conference Only - Drug Developer Pricing: EUR 2799.00,
Conference + Focus Day OR Workshop Day - Small Biotech Pricing: EUR 4246.00,
Conference Only - Small Biotech Pricing: EUR 2799.00,
Conference + Focus Day OR Workshop Day - Academic Pricing: EUR 3896.00,
Conference Only - Academic Pricing: EUR 2399.00,
Conference + Focus Day OR Workshop Day - Service Provider Pricing: EUR 5446.00,
Conference Only - Service Provider Pricing: EUR 3499.00

Speakers: Ajan Reginald Chief Executive Officer  Roquefort Therapeutics plc, Alexander Zehnder CEO  CureVac, Amit Benazraf Business Development Lead  Mana Bio, Anette Sommer Senior Director, Emerging Science and Innovation, Lead Oncology Europe  Pfizer, Arun Kumar Preclinical Vaccines Development Lead  CEPI, Carsten Rudolph CEO  Ethris, Chris Cardon CEO  Ziphius Vaccines, Claudia Lindemann Director - Non-Clinical Safety  BioNTech SE, Covadonga Paneda Chief Operating Officer  Altamira Therapeutics, Daniel Tondera Head of Biology  Pantherna Therapeutics, Duccio Medini R3 Program Director  Wellcome Leap, Estelle Beguin Director - Technology Research  Ethris, Fernando Ulloa Montoya Head - Data and Computational Science  mRNA Center of Excellence, Sanofi, Gad Berdugo Managing Partner; Strategic Advisor  Explorium Capital LLC; Nutcracker Therapeutics, Jenny van Asbeck CEO  Mercurna, Jens Demand Director - Product Life Cycle  PATH, Jerry Zhang Vice President - Formulation Research and Development  Abogen Biosciences, Ka-Wai Wan Senior Pharmaceutical Assessor  Medicines and Healthcare Products Regulatory Agency (MHRA), Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy  European Medicines Agency, Maren von Fritschen Head - Regulatory Policy Europe  Moderna, Martin Friede Initiative for Vaccine Research Coordinator  World Health Organization - WHO, Martin Friede Initiative for Vaccine Research Coordinator  World Health Organization - WHO, Myriam Mendila Chief Development Officer  CureVac, Rajesh Krishnan Director of Formulations  Providence Therapeutics Inc., Sam Deutsch Executive Vice President, Research and Early Development  Nutcracker Therapeutics,  Sanjay Singh CEO  Gennova Biopharmaceuticals, Simone Blayer Global Head - CMC  PATH, Sonia Golombek Senior Research and Development Manager  Elastrin Therapeutics, Sven Jager Computational Science Manager  Sanofi, Swarnendu Kaviraj Associate Director - R and D  Gennova Biopharmaceuticals, Thomas Langenickel Chief Medical Officer  Ethris GmbH, Tim Sparey Managing Director  VaxEquity, Wade Davis VP - Computational Science  Moderna, Yaniv Erlich CEO  Eleven Therapeutics, Ana Rebane Professor  University of Tartu, Camilla Foged Professor  University of Copenhagen, Chantal Pichon Professor and Head of Research unit  University of Orleans, Lorenzo Franceschini Co-Founder / mRNA Development and Production Lead  Vrije University Brussels, Mark Dickman Professor  University of Sheffield, Nawaz Muhammad Senior Scientist  University of Salzburg, Simone Spuler Professor  Charité Universitätsmedizin Berlin, Tim Beissert Head Immune and Gene Therapy Development  TRON, Ioana Panait Research Analyst  Beacon Targeted Therapies, Matthias Lubbert Principle Engineer - Process  KNAUER Wissenschaftliche Geräte GmbH, May Guo Chief Commercial Officer  Areterna

Others Details

Brochure: https://go.evvnt.com/1951095-3?pid=6581